How promising research becomes an investable opportunity

A positive laboratory result gives an investor or organisation a reason to look closely at a technology. But the harder decision is whether to commit resources to developing it. That requires evidence that the technology can meet practical requirements at a viable cost, and clarity about whether its intellectual property (IP) supports the intended business.

At NTU Innovation and Entrepreneurship (I&E), the Technology Development and IP Management teams work with researchers to address these questions together, where technical evidence and IP strategy evolve alongside each other as the commercial application becomes clearer.

Proving what matters

Dr Michelle Zhang, Head of NTU I&E’s Technology Development team, begins with the need a technology could meet. Alongside the strength of the science, the team considers its advantage over existing solutions and whether there is a realistic path to adoption. The intended application gives the assessment a practical focus, ensuring the technology is developed with customer requirements in mind.

“We do not expect every technology to be fully developed before engaging the market,” she says. “Instead, we identify the critical uncertainties or technical barriers that could prevent adoption and focus development resources on addressing those first.”

A recurring challenge, she adds, is a technology that performs well in the laboratory but needs further work to become reliable or scalable enough for industry. A manufacturer may need results that can be reproduced under its processing conditions, at a cost that makes adoption worthwhile. Compatibility with existing production processes can be as consequential as the original performance result. 

NTU I&E works with the research team to identify these development gaps and set validation milestones, using proof-of-concept funding or other development support where appropriate. A scale-up problem, for example, calls for evidence that performance can be sustained as production increases. Other technologies may need testing with real-world samples or progress towards regulatory or clinical milestones.

Protecting the advantage as it develops

At the same time, refining a technology for practical use may generate new inventions, while proof-of-concept work can provide data to support stronger patent claims. NTU I&E’s IP Management team works alongside Technology Development team to capture these advances and assess whether the existing IP position needs to be strengthened.

“IP strategy is not set once at filing and forgotten. It evolves alongside the technology,” says Ms Christina Gee, who leads NTU I&E’s IP Management team. 

As Technology Development assesses potential uses and markets, IP Management shapes the patent claims — the statements defining the protection sought — and the filing strategy around those same opportunities. Further development may prompt revised claims or additional filings as new inventions and target markets emerge.

Ms Gee highlights that a patent application must undergo examination, during which its claims may change. The scope ultimately granted determines how much exclusivity the patent provides. A business needs to consider whether those claims cover commercially useful features and how readily competitors could work around them. The strength of the commercial asset also depends on evidence of market demand and a team with a credible plan to bring it to market.

Clarifying the rights available

For a prospective licensee or investor, the next question is which rights can be made available for the intended business. This requires clarity about ownership and any existing commitments that affect what NTU can offer.

University inventions may involve co-owners or research collaborators, as well as funding obligations. NTU I&E helps clarify these through IP records and due diligence, identifying potential risks early and addressing them where possible. Partners also need to understand where protection is being sought or has been granted, and whether further filings are planned.

In  addition,  these  discussions  need to  account  for  the  technology’s  stage  of development. Patent protection can coexist with substantial work still to be done on validation, scale-up or product development. Understanding that work helps both sides assess the further resources required and their respective roles.

The university’s academic responsibilities belong in the conversation too. “Universities also need to balance commercial IP protection with their academic mission, including researchers’ need to publish their work,” Ms Gee says. Clarifying expectations early helps the parties plan a collaboration that takes these needs into account.

Engaging while choices are still open

“Industry input is often most valuable before the technology is fully market-ready, when there is still flexibility to influence its development,” Dr Zhang says, highlighting that external partners’ knowledge of cost targets or manufacturing constraints can shape development requirements. At later stages, partners may offer testing environments and pilot opportunities, or the manufacturing expertise and distribution channels needed for adoption.

Such involvement also strengthens the evidence available to future partners and investors. Dr Zhang points to independent external validation as a particularly powerful source of confidence: testing or adoption by a credible industry partner adds evidence beyond laboratory results. 

For potential partners, early engagement with NTU I&E offers a chance to help define the evidence on which a future investment or licensing decision will depend. “Overall, our objective is to reduce the key uncertainties progressively,” Dr Zhang adds. “Every development milestone should ideally increase technical confidence, strengthen the IP position and bring the technology closer to a clearly identifiable commercial opportunity.”Read the full  newsletter or subscribe to NTU I&E for the latest updates, events and programmes.